. Author manuscript; available in PMC: 2012 Apr 17.

Published in final edited form as: Nat Rev Cardiol. 2010 Oct 26;7(12):686–698. doi: 10.1038/nrcardio.2010.161

Table 6. Clinical trials investigating effects of antihypertensive therapy on cognitive function.

Trial	Follow-up period	n	Mean age (years)	% women	Antihypertensive therapies studied	Effect of treatment on outcomes
HYVET-COG⁷⁷	2.2 years	3,336	84	60	Indapamide or perindopril vs placebo	No effect
SHEP⁹²	14 years	455	74	NA	Chlortalidone, atenolol, reserpine	No effect
MRC⁹³	5.8 years	2,584	69.5	58	Diuretic vs BB vs placebo	No effect
Syst-Eur⁹⁴	2 years	2,418	70	65–66	Nitrendipine with possibility to add enalapril and HCTZ vs placebo	Positive
PROGRESS⁹⁶	4 years	6,105	64	30	ACE inhibitor ± diuretic vs placebo	Positive in those with stroke
HOPE⁹⁸	4.5 years	9,297	66 ± 7	27	ACE inhibitor vs placebo	Positive
SCOPE¹⁰⁰	3.7 years	4,964	76	66	ARB vs placebo	No effect
PRoFESS¹⁰⁴	2.4 years	20,332	66	36	ARB vs placebo	No effect
Fogari et al.¹¹²	24 weeks	120	81	55	Losartan vs atenolol	Positive
Tedesco et al.¹¹⁴	2 years	69	52	48	Losartan vs HCTZ	Positive
Syst-Eur follow-up¹¹⁶	4 years	2,902	68	66	Nitrendipine with possibility to add enalapril and HCTZ vs placebo	Positive
Muldoon et al.¹¹⁷	6 weeks	88	43	0	BB vs diuretic vs ACE inhibitor vs CCB vs centrally acting sympatholytic agent	Positive
Fogari et al.¹¹⁸	16 weeks	144	70	55	ARB vs ACE inhibitor	Positive

Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; BB, β-blocker; CCB, calcium-channel blocker; HCTZ, hydrochlorothiazide; HOPE, Heart Outcomes Prevention Evaluation; HYVET-COG, Hypertension in the Very Elderly Trial cognitive function assessment; MRC, Medical Research Council; NA, not available; PROGRESS, Perindopril Protection against Recurrent Stroke Study; PRoFESS, Prevention Regimen for Effectively Avoiding Second Strokes; SCOPE, Study on Cognition and Prognosis in the Elderly; SHEP, Systolic Hypertension in the Elderly Program; Syst-Eur, Systolic Hypertension in Europe.